

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-40) GLEPAGLUTIDE

PRONUNCIATION glep" a gloo' tide

THERAPEUTIC CLAIM Treatment of short bowel syndrome

CHEMICAL NAMES

1. L-Lysinamide, L-histidylglycyl-L- α -glutamylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-seryl-L- α -glutamyl-L-leucyl-L-seryl-L-threonyl-L-isoleucyl-L-leucyl-L- α -aspartyl-L-alanyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L- α -aspartyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-alanyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L- α -aspartyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-
2. mutated human glucagon like peptide-2 (GLP-2) analogue with a C-terminal hexalysine addition; [2-glycine(A>G),3-glutamic acid(D>E),5-threonine(S>T),8-serine(D>S),10-leucine(M>L),11-alanine(N>A),16-alanine(N>A),24-alanine(N>A),28-alanine(Q>A)]human glucagon-like peptide 2 (GLP-2) fusion peptide with hexalysinamide

STRUCTURAL FORMULA

Sequence

HGEGTFSSSEL ATILDALAAR DFIAWLIATK ITDKKKKKK 39

Modified residue

K lysinamide

MOLECULAR FORMULA $C_{197}H_{325}N_{53}O_{55}$

MOLECULAR WEIGHT 4318 Da

TRADEMARK None as yet

SPONSOR Zealand Pharma A/S

CODE DESIGNATION ZP1848

CAS REGISTRY NUMBER 914009-86-2

UNII 4M3C1913N6

SCS